SCHEMBL19327352

SCHEMBL19327352

CN(C)CCCOc1ccc(/C=C/c2ccc([N+](=O)[O-])cc2)cc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 3/20 0.65
KCNH2 Q12809 4/20 0.56
MAOB P27338 2/20 0.53
MAOA P21397 1/20 0.53
APP P05067 2/20 0.52
HRH3 Q9Y5N1 2/20 0.52
LMNA P02545 2/20 0.51
MAPT P10636 2/20 0.51
ALDH1A1 P00352 2/20 0.51
SMN1; SMN2 Q16637 2/20 0.51
MEN1 O00255 1/20 0.51
NPC1 O15118 1/20 0.51
RAB9A P51151 1/20 0.51
KMT2A Q03164 1/20 0.51
NPSR1 Q6W5P4 1/20 0.51
BCHE P06276 1/20 0.50
ACHE P22303 1/20 0.50
CHRNB2 P17787 1/20 0.50
CHRNA4 P43681 1/20 0.50
KDM4E B2RXH2 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17609116 1.00 PTGS2 (0.65) PTGS2KCNH2MAOBMAOAAPP
SCHEMBL1728679 0.91 KCNH2 (0.65) KCNH2HRH3MAPTALDH1A1SMN1; SMN2
SCHEMBL17609051 0.87 NFE2L2 (0.63) PTGS2MAOBMAOAAPPHRH3
SCHEMBL19327344 0.87 NFE2L2 (0.63) PTGS2MAOBMAOAAPPHRH3
SCHEMBL9827026 0.85 PTGS2 (0.77) PTGS2MAOBLMNAMAPTALDH1A1
SCHEMBL9827029 0.85 PTGS2 (0.77) PTGS2MAOBLMNAMAPTALDH1A1
SCHEMBL1962562 0.84 KCNH2 (0.68) PTGS2KCNH2HRH3MAPTCHRNB2
SCHEMBL8491464 0.83 ALDH1A1 (0.52) PTGS2KCNH2MAOBHRH3LMNA
SCHEMBL8491471 0.83 ALDH1A1 (0.52) PTGS2KCNH2MAOBHRH3LMNA
SCHEMBL19327365 0.82 BCHE (0.53) PTGS2MAOBMAOAAPPHRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170260126-A1 SQUALENE COMPOUNDS AS MODULATORS OF LDL-RECEPTOR EXPRESSION UNIV OXFORD INNOVATION LTD (GB) 2017-09-14 US claimed
US-20170260126-A1 SQUALENE COMPOUNDS AS MODULATORS OF LDL-RECEPTOR EXPRESSION UNIV OXFORD INNOVATION LTD (GB) 2017-09-14 US disclosed
US-20170260126-A1 SQUALENE COMPOUNDS AS MODULATORS OF LDL-RECEPTOR EXPRESSION UNIV OXFORD INNOVATION LTD (GB) 2017-09-14 US disclosed
US-20170260126-A1 SQUALENE COMPOUNDS AS MODULATORS OF LDL-RECEPTOR EXPRESSION UNIV OXFORD INNOVATION LTD (GB) 2017-09-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170260126-A1 SQUALENE COMPOUNDS AS MODULATORS OF LDL-RECEPTOR EXPRESSION LDLR, NR1H2, SREBF1 PTGS2 798/4885KCNH2 4178/4885MAOB 3074/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.